RxDoctor Payments DataLook up a doctor →

James Macdonald, MD

Dermatology · Lehi, UTNPI 1750517736

Payments from drug & device makers

$314,491in general payments, 2019–2025

Across 682 payments — averaging $461.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$286K
  • Dr.reddy's Laboratories,inc.$9K
  • Arcutis Biotherapeutics, Inc.$6K
  • Galderma Laboratories, L.p.$4K
  • UCB, Inc.$3K
  • Johnson & Johnson$1K
  • plus $5K from 26 others

What the payments were for

  • Consulting fees$3,90027%
  • Food & beverage$9,73968%
  • Education$6384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$314,491 in reported general payments places this provider in the 90th percentile of 163 dermatology providers in Utah.

See all dermatology providers in Utah

Medicare billing

Part B allowed, 2024
$555,594
Medicare patients
2,560
Services billed
8,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib12$105,856
Dupixent PenDupilumab26$99,644
Triamcinolone Acetonide333$4,770
Doxycycline Hyclate56$1,878
Metronidazole36$1,726
Ketoconazole115$1,634
Clobetasol Propionate51$1,503
Hydrocortisone46$792
Doxepin Hcl14$764
Spironolactone28$630
Minoxidil25$514
ValacyclovirValacyclovir Hcl13$470
Dutasteride11$341
Terbinafine Hcl33$255
Mupirocin15$133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$286,035$105,85612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 163 dermatology providers in Utah.

Other dermatology in Lehi

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →